Evidence map›Paper›PMID 17485516›Full record

ArticleThe Journal of experimental medicine2007

Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands.

Ian R Humphreys, Carl de Trez, April Kinkade, Chris A Benedict, Michael Croft, Carl F Ware

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The Journal of experimental medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 121 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Immune surveillance of cytomegalovirus in tissues.Cellular & molecular immunology · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. A new clustering method identifies multiple sclerosis-specific T-cell receptors.Annals of clinical and translational neurology · 2021
    Article
  15. Observational
  16. Review
  17. Article
  18. Human Cytomegalovirus Interleukin 10 Homologs: Facing the Immune System.Frontiers in cellular and infection microbiology · 2020
    Review
  19. Review
  20. Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ian R HumphreysDivision of Molecular Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA.
Carl de Trez
April Kinkade
Chris A Benedict
Michael Croft
Carl F Ware
La Jolla Institute for Immunology · US

Funding

Anti-herpesvirus Signaling by LTalphabeta/LIGHT CytokinesR01AI048073 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 2001 to 2016
$7.0M
Lymphotoxin alpha Beta and LIGHT cytokine systemsR37AI033068 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 2003 to 2012
$4.2M
Regulation of T Cell Tolerance by OX40R01CA091837 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2002 to 2012
$2.5M
Modulating Lymphotoxins for Viral DefensesR01AI057840 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI WARE, CARL F · 2005 to 2009
$2.4M
TNFR Members in T Cell Immunity to VacciniaR01AI067341 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2006 to 2010
$2.3M
Training in ImmunologyT32AI060536 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HEDRICK, STEPHEN M · 2006 to 2010
$1.1M
TNFR Members in T Cell Immunity to VacciniaR56AI067341 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROFT, MICHAEL · 2012 to 2012
$348k
NCI NIH HHS CA911837NCI NIH HHS R01 CA091837NIAID NIH HHS AI057840NIAID NIH HHS AI48073NIAID NIH HHS AI67341NIAID NIH HHS R01 AI048073NIAID NIH HHS R01 AI057840NIAID NIH HHS R01 AI067341NIAID NIH HHS R37 AI033068NIAID NIH HHS R37 AI33068NIAID NIH HHS R56 AI067341NIAID NIH HHS T32 AI060536
6 · The paper itself

Abstract

The salivary glands represent a major site of cytomegalovirus replication and transmission to other hosts. Despite control of viral infection by strong T cell responses in visceral organs cytomegalovirus replication continues in the salivary glands of mice, suggesting that the virus exploits the mucosal microenvironment. Here, we show that T cell immunity in the salivary glands is limited by the induction of CD4 T cells expressing the regulatory cytokine interleukin (IL)-10. Blockade of IL-10 receptor (IL-10R) with an antagonist antibody dramatically reduced viral load in the salivary glands, but not in the spleen. The mucosa-specific protection afforded by IL-10R blockade was associated with an increased accumulation of CD4 T cells expressing interferon gamma, suggesting that IL-10R signaling limits effector T cell differentiation. Consistent with this, an agonist antibody targeting the tumor necrosis factor receptor superfamily member OX40 (TNFRSF4) enhanced effector T cell differentiation and increased the number of interferon gamma-producing T cells, thus limiting virus replication in the salivary glands. Collectively, the results indicate that modulating effector T cell differentiation can counteract pathogen exploitation of the mucosa, thus limiting persistent virus replication and transmission.

Indexed as

AnimalsAntibodiesCD4-Positive T-LymphocytesCell DifferentiationDNA PrimersFemaleFlow CytometryHerpesviridae InfectionsInterferon-gammaInterleukin-10MiceMice, Inbred C57BLMuromegalovirusReceptors, Interleukin-10Receptors, OX40Reverse Transcriptase Polymerase Chain ReactionAntibodiesDNA PrimersInterferon-gammaInterleukin-10Receptors, Interleukin-10Receptors, OX40Tnfrsf4 protein, mouse

Identifiers

PMID17485516
PMCPMC2118568
OpenAlexW2140357666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.